查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1964004

尿道感染检测市场－全球产业规模、份额、趋势、机会、预测：按类型、最终用途、地区和竞争格局划分，2021-2031年

Urinary Tract Infection Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By End use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球尿道感染检测市场预计将从 2025 年的 6.3657 亿美元成长到 2031 年的 8.1527 亿美元，复合年增长率为 4.21%。

此领域涵盖多种诊断技术，例如尿液检查、尿液培养和分子诊断，用于识别泌尿道病原体。推动该领域发展的关键因素包括全球尿道感染发病率的上升，尤其是在女性和老年人群中，以及医院获得性感染（例如导尿管相关感染）的增加。此外，对能够实现即时治疗的快速就地检验解决方案的迫切需求也加速了这些解决方案的普及。正如美国泌尿系统协会在2024年指出的那样，全球每年估计发生1.5亿例尿道感染，医疗保健总成本高达60亿美元。

市场概览
预测期 2027-2031
市场规模：2025年 6.3657亿美元
市场规模：2031年 8.1527亿美元
复合年增长率：2026-2031年 4.21%
成长最快的细分市场 膀胱炎
最大的市场 北美洲

儘管成长指标强劲，但传统快速筛检工具的诊断准确性仍面临许多挑战。传统尿液测试纸的敏感度和特异性往往不足，导致假阴性或假阳性率较高，进而造成漏诊或不必要的抗生素使用。因此，这些限制可能迫使人们依赖耗时的尿液培养检测进行检验，延误治疗，并阻碍在註重成本的医疗环境中广泛采用快速诊断方法。

市场驱动因素

全球尿道感染（ UTI）发生率的不断上升是推动市场成长的主要因素，也使得医疗机构对高通量诊断能力的需求日益增长。抗菌素抗药性（AMR）问题的日益严重进一步加剧了这一需求，使得经验性治疗难以实施，因此必须准确检测病原体以避免尿路败血症和肾盂肾炎等併发症。随着标准抗生素对抗药性菌株的疗效逐渐降低，临床上越来越依赖准确的筛检和培养确诊。根据美国食品药物管理局（FDA）2024年10月发布的关于常见感染疾病新治疗方法的声明，大约一半的女性一生中至少会经历一次尿路感染疾病，预计对急性及復发性尿路感染诊断服务的需求将持续稳步增长。

同时，就地检验技术的快速发展正在革新这一领域，满足了人们对速度和诊断准确性的迫切需求。医疗服务提供者正逐渐抛弃需要数天才能出结果的传统方法，转而选择能够即时做出临床决策的分子检测和快速表型检测。美国疾病管制与预防中心 (CDC) 于 2024 年 11 月发布的最新抗生素使用情况报告印证了这一转变，该报告显示，2016 年至 2023 年间，Medicare 索赔中多次分子尿道感染检测的数量增加了 50 倍以上。此外，快速药敏试验技术的创新正在加速这项转变。例如，BioMérieux 公司在 2024 年报告称，其 VITEK REVEAL AST 系统平均可在 5.5 至 6 小时内提供某些革兰氏阴性菌的可操作数据，从而显着缩短标靶治疗的时间。

市场挑战

全球尿道感染检测市场的主要障碍在于标准快速筛检技术缺乏诊断准确性。儘管尿液测试纸检测因其价格低廉、速度快而被广泛应用，但其灵敏度和特异性往往不足以做出明确的医学诊断。这种技术缺陷迫使医护人员依赖耗时的尿液培养检测来确认结果，从而有效地抵消了即时照护现场。因此，由于临床医生不能仅依赖可能存在误差的快速诊断来製定治疗决策，市场在全面过渡到分散式检查模式方面面临许多困难。

这种准确性的不足导致了显着的营运效率损失和临床风险，从而阻碍了市场成长。高频率的假阳性结果会导致不必要的抗生素处方，而假阴性结果则会导致需要紧急治疗的患者延迟治疗。近期的数据凸显了这种诊断缺陷的严重性。 2025年，美国泌尿系统协会报告称，诸如白血球酯酶阳性和亚硝酸盐阳性等标准尿液检查标记在检测实际感染疾病的阳性预测率低于50%。这些数据表明，目前的快速检测工具经常无法区分真正的感染疾病和污染，迫使医疗系统维持高成本且劳动密集的参考检查室流程，并降低了市场的整体容量。

市场趋势

家庭和自测环境的普及正在改变全球尿道感染 ( UTI) 检测市场，使医疗保健服务分散化，并减轻基层医疗机构的负担。这一趋势的特点是消费者诊断试剂盒和药房管理的检测服务激增，使患者无需前往全科医生处即可获得快速筛检和即时治疗。在推行赋能社区药剂师政策的地区，这种转变尤其显着，从而在传统医院之外建立了一个新的高成长管道。根据《药剂师》杂誌2025年4月报告的「药局优先」咨询计画第一年的数据，2024年2月至2025年1月期间，英格兰共进行了607,646次非复杂性尿道感染的咨询，证实了消费者对分散式检查管道的使用显着增加。

同时，克服标准微生物检测方法性能限制的需求正推动市场向分子和基因组诊断技术发生重大转变。儘管传统方法仍占据主导地位，但检测需氧微生物的难度以及快速提供抗生素敏感性数据的挑战，正加速将次世代定序(NGS) 和先进的基因组平台应用于常规诊断。这些先进技术提高了灵敏度和特异性，能够准确地识别传统培养方法经常漏诊的病原体。这降低了抗生素无效使用和復发性行为感染的风险。根据 Biotear 公司 2025 年 9 月发布的先进检测服务的公告，标准尿液培养的失败率约为 30%。这种诊断缺陷正积极推动临床转向更可靠的基因组为基础的检测解决方案。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球尿道感染检测市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依类型（尿道炎、膀胱炎、肾盂肾炎）
    • 依最终用途（全科医生、泌尿系统、泌尿系统/妇科医生、医院检查室、参考检查室、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美尿道感染检测市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲尿道感染检测市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区尿道感染检测市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲尿道感染检测市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲尿道感染检测市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球尿道感染检测市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • QIAGEN NV
  • Accelerate Diagnostics, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • Siemens Healthcare GmbH
  • Randox Laboratories Ltd.
  • Thermo Fisher Scientific, Inc.
  • BIOMeRIEUX
  • T2 Biosystems, Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 21964

The Global Urinary Tract Infection Testing Market is projected to expand from USD 636.57 Million in 2025 to USD 815.27 Million by 2031, reflecting a compound annual growth rate of 4.21%. This sector includes various diagnostic techniques such as urinalysis, urine culture, and molecular diagnostics intended to identify pathogens within the urinary tract. Growth is largely driven by the increasing global incidence of urinary tract infections, especially among women and the elderly, as well as a rise in hospital-acquired cases like those associated with catheters. Additionally, the adoption of testing solutions is being hastened by the urgent need for rapid point-of-care options that enable immediate treatment. As noted by the American Urological Association in 2024, an estimated 150 million urinary tract infections occur annually worldwide, resulting in healthcare costs totaling 6 billion dollars.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 636.57 Million
Market Size 2031USD 815.27 Million
CAGR 2026-20314.21%
Fastest Growing SegmentCystitis
Largest MarketNorth America

Despite these positive growth metrics, the market encounters a substantial obstacle regarding the diagnostic precision of traditional rapid screening tools. Conventional urine dipstick tests frequently demonstrate insufficient sensitivity and specificity, causing high instances of false negatives or positives that may lead to untreated conditions or unwarranted antibiotic usage. Consequently, this limitation forces a dependence on slower urine cultures for verification, delaying appropriate therapy and potentially impeding the broader uptake of rapid diagnostic methods in cost-conscious medical environments.

Market Driver

The rising global prevalence of urinary tract infections serves as a major market propellant, creating a need for high-volume diagnostic capacities in medical facilities. This demand is further amplified by the escalating issue of antimicrobial resistance (AMR), which makes empirical treatment difficult and necessitates exact pathogen detection to avoid complications like urosepsis or pyelonephritis. As standard antibiotics lose efficacy against resistant strains, clinical reliance on accurate screening and culture confirmation has grown. According to an October 2024 announcement by the U.S. Food and Drug Administration regarding new treatments for uncomplicated infections, roughly half of all women will suffer at least one such infection during their lives, ensuring a steady and increasing demand for diagnostic services to handle acute and recurrent cases.

Concurrently, the surge in point-of-care testing technologies is revolutionizing the sector by fulfilling the urgent requirement for speed and diagnostic accuracy. Medical providers are progressively moving away from traditional techniques that take days to yield results, opting instead for molecular and rapid phenotypic tests that facilitate instant clinical decisions. This shift is highlighted by the Centers for Disease Control and Prevention's November 2024 update on antibiotic use, which noted a greater than 50-fold increase in Medicare claims for multiplex molecular urinary tract infection tests between 2016 and 2023. Additionally, innovations in rapid susceptibility testing are speeding up this transition; for instance, bioMerieux reported in 2024 that the VITEK REVEAL AST System can provide actionable data for specific gram-negative bacteria within an average of 5.5 to 6 hours, greatly improving the timeline for targeted treatments.

Market Challenge

The principal obstacle restricting the Global Urinary Tract Infection Testing Market is the inadequate diagnostic accuracy found in standard rapid screening techniques. Although urine dipstick tests are commonly used due to their affordability and speed, they often lack the sensitivity and specificity needed for conclusive medical diagnoses. This technical deficiency compels healthcare practitioners to rely on slow urine cultures to confirm findings, essentially canceling out the immediacy intended by point-of-care solutions. As a result, the market faces difficulties in fully shifting towards decentralized testing models, as clinicians are unable to trust treatment decisions exclusively to rapid diagnostics that are susceptible to errors.

This absence of precision leads to considerable operational inefficiencies and clinical dangers that inhibit market growth. High occurrences of false-positive results frequently cause unnecessary antibiotic prescriptions, whereas false negatives delay treatment for patients in need of urgent attention. The magnitude of this diagnostic shortcoming is highlighted by recent data; the American Urological Association reported in 2025 that standard urinalysis markers, such as positive leukocyte esterase and nitrites, demonstrated positive predictive values of less than 50% for detecting actual infections. Such statistics demonstrate that current rapid tools frequently fail to differentiate between genuine infection and contamination, forcing healthcare systems to sustain costly, labor-intensive reference laboratory processes that reduce overall market throughput.

Market Trends

The proliferation of home-based and self-testing environments is significantly transforming the Global Urinary Tract Infection Testing Market by decentralizing care access and reducing the pressure on primary medical facilities. This movement is defined by the growing accessibility of direct-to-consumer diagnostic kits and pharmacy-managed testing services, enabling patients to receive rapid screening and immediate therapy without visiting a general practitioner. This transition is especially apparent in areas adopting policies that empower community pharmacists, establishing a new, high-volume growth channel beyond traditional hospitals. As reported by The Pharmacist in April 2025 regarding the first year of Pharmacy First consultations, 607,646 consultations for uncomplicated urinary tract infections were conducted via the service in England between February 2024 and January 2025, underscoring substantial consumer uptake of decentralized testing routes.

At the same time, the market is undergoing a notable pivot toward molecular and genomic diagnostic techniques, motivated by the necessity to surpass the performance constraints of standard microbiological methods. While traditional practices remain prevalent, their failure to detect fastidious organisms or supply rapid antimicrobial susceptibility data has hastened the adoption of next-generation sequencing (NGS) and advanced genomic platforms in routine diagnostics. These advanced technologies provide enhanced sensitivity and specificity, allowing for the accurate identification of pathogens often missed by conventional cultures, thereby reducing the risks of ineffective antibiotic use and recurrent infections. According to a September 2025 announcement by Biotia regarding their advanced test offering, standard urine cultures fail approximately 30% of the time, a diagnostic deficiency that is actively driving the clinical shift toward more dependable genomic-based testing solutions.

Key Market Players

  • QIAGEN NV
  • Accelerate Diagnostics, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • Siemens Healthcare GmbH
  • Randox Laboratories Ltd.
  • Thermo Fisher Scientific, Inc.
  • BIOMeRIEUX
  • T2 Biosystems, Inc

Report Scope

In this report, the Global Urinary Tract Infection Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Urinary Tract Infection Testing Market, By Type

  • Urethritis
  • Cystitis
  • Pyelonephritis

Urinary Tract Infection Testing Market, By End use

  • General Practitioners (GPs)
  • Urologists
  • Urogynecologists
  • Hospital Laboratories
  • Reference Laboratories
  • Others

Urinary Tract Infection Testing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Urinary Tract Infection Testing Market.

Available Customizations:

Global Urinary Tract Infection Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Urinary Tract Infection Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Urethritis, Cystitis, Pyelonephritis)
    • 5.2.2. By End use (General Practitioners (GPs), Urologists, Urogynecologists, Hospital Laboratories, Reference Laboratories, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Urinary Tract Infection Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By End use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Urinary Tract Infection Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By End use
    • 6.3.2. Canada Urinary Tract Infection Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By End use
    • 6.3.3. Mexico Urinary Tract Infection Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By End use

7. Europe Urinary Tract Infection Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By End use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Urinary Tract Infection Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By End use
    • 7.3.2. France Urinary Tract Infection Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By End use
    • 7.3.3. United Kingdom Urinary Tract Infection Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By End use
    • 7.3.4. Italy Urinary Tract Infection Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By End use
    • 7.3.5. Spain Urinary Tract Infection Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By End use

8. Asia Pacific Urinary Tract Infection Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By End use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Urinary Tract Infection Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By End use
    • 8.3.2. India Urinary Tract Infection Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By End use
    • 8.3.3. Japan Urinary Tract Infection Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By End use
    • 8.3.4. South Korea Urinary Tract Infection Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By End use
    • 8.3.5. Australia Urinary Tract Infection Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By End use

9. Middle East & Africa Urinary Tract Infection Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By End use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Urinary Tract Infection Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By End use
    • 9.3.2. UAE Urinary Tract Infection Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By End use
    • 9.3.3. South Africa Urinary Tract Infection Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By End use

10. South America Urinary Tract Infection Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By End use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Urinary Tract Infection Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By End use
    • 10.3.2. Colombia Urinary Tract Infection Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By End use
    • 10.3.3. Argentina Urinary Tract Infection Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By End use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Urinary Tract Infection Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. QIAGEN NV
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Accelerate Diagnostics, Inc.
  • 15.3. Bio-Rad Laboratories, Inc.
  • 15.4. F. Hoffmann-La Roche Ltd.
  • 15.5. Danaher Corporation
  • 15.6. Siemens Healthcare GmbH
  • 15.7. Randox Laboratories Ltd.
  • 15.8. Thermo Fisher Scientific, Inc.
  • 15.9. BIOMeRIEUX
  • 15.10. T2 Biosystems, Inc

16. Strategic Recommendations

17. About Us & Disclaimer